

Erector Spinae Plane Block Decreases Pain and Opioid Consumption in Breast Surgery: Systematic Review

Hassan ElHawary, MSc* Kenzy Abdelhamid* Fanyi Meng, MD† Jeffrey E. Janis, MD, FACS‡

Background: Adequate control of acute postoperative pain is crucial in breast surgeries, as it is a significant factor in the development of persistent chronic pain. Inadequate postoperative pain control increases length of hospital stays and risk of severe complications. Erector spinae plane block (ESPB) is a novel regional block that has the ability to sufficiently block unilateral multidermatomal sensation from T1 to L3. By reviewing the literature on ESPB, this paper aimed to elucidate its efficacy in breast surgery analgesia and its role in addressing the opioid crisis in North America.

Methods: PUBMED, EMBASE, and Cochrane databases were systematically searched for relevant articles according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Inclusion criteria included any articles that described ESPB in breast surgery. Exclusion criteria composed of articles that exclusively discussed other kinds of regional blocks.

Results: Thirty-two articles including 6 randomized controlled trials were included in this review. ESPB demonstrated superior pain control and less opioid consumption compared with tumescent anesthesia or using no block. However, ESPB showed lower efficacy in pain control compared with pectoral nerve block. Patients experienced less nausea and vomiting and were overall more satisfied with ESPB compared with other pain control modalities. The vast majority of the studies reported the ease of ESPB administration, and only 1 case presented with a complication.

Conclusions: ESPB is a promising form of regional anesthesia that can decrease postoperative pain and opioid consumption when used as part of multimodal pain analgesia for patients undergoing breast surgery. (*Plast Reconstr Surg Glob Open 2019;7:e2525; doi: 10.1097/GOX.00000000002525; Published online 27 November 2019.*)

INTRODUCTION

Breast surgeries encompass a wide scope of procedures from breast enhancement to oncologic mastectomy and reconstruction. One common feature they share is the significant postoperative pain experienced by patients, with some studies showing that over 50% of patients undergoing mastectomy and reconstruction experience pain up to 1 year postoperatively.^{1–3} Although breast surgeries can significantly improve quality of life and be curative in cases of malignancy,^{4,5} acute and chronic postoperative pain can

From the *Faculty of Medicine, McGill University, Montreal, Quebec, Canada; †Department of Plastic and Reconstructive Surgery McGill University Health Centre, Montreal, Quebec, Canada; and ‡Department of Plastic Surgery, Ohio State University Wexner Medical Center, Columbus, Ohio.

Received for publication August 30, 2019; accepted September 11, 2019.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1097/GOX.00000000002525

be severe and cause functional impairment.^{6,7} Although research in breast surgery is constantly evolving to provide better aesthetic outcomes with fewer complications,^{8,9} postoperative pain still remains a burden for patients and an unresolved challenge for surgeons.^{10,11}

The past few decades have witnessed a surge in opioid consumption as a method of postoperative analgesia. Alarmingly, levels of addiction and opioid-related mortality have reached over 42,000 deaths annually in the United States alone.^{12,13} The opioid epidemic has fueled continuous efforts in improving pain management in plastic surgery procedures and specifically breast surgery.^{14,15} A case–control study of almost half a million individuals who underwent plastic or reconstructive surgery found that patients undergoing breast surgeries are the most susceptible to both acute and prolonged postoperative pain.¹⁶ Although many patients prefer tolerating pain rather than overconsuming opioids, the literature shows that breast surgeons usually overprescribe them.^{17,18} Therefore, it is the physician's responsibility to seek benign pain control

Disclosure: Dr. Jeffrey E. Janis receives royalties from Thieme Publishing. None of the other authors have any financial disclosures. modalities to ease patients' recovery and fight the opioid epidemic.

Although using regional blocks as an adjunct form of analgesia existed for many years, they have only recently increased in popularity as a method of postoperative pain management.^{19,20} This change parallels the surge in interest for quality improvement initiatives and Enhanced Recovery after Surgery pathways in hospitals to improve outcomes and increase patient satisfaction. A recent meta-analysis demonstrated superior pain control with regional blocks compared with opioid-based analgesia.²⁰ In addition, they allow for earlier patient mobilization, faster return to function, and carry no risk of addiction and overdose.²¹

In surgeries for breast cancer specifically, there is further evidence that regional anesthesia attenuates the surgical response system and can reduce the progression of malignancy.²² Several regional nerve blocks have been proposed for breast analgesia.²³ Popular examples include the pectoral nerve blocks (PECS I and II) and paravertebral blocks (PVBs).²⁴ Although the efficacy of these blocks has been well demonstrated, they all incur limitations, such as increased hematoma rates, risk of pleural punctures, and intravascular injections.²⁵⁻²⁷ Furthermore, the spread of local anesthetic through the fascial planes in PECS can prevent the electrocautery from functioning at an acceptable level.²⁸ A recent systematic review of fascial plane blocks in breast surgeries showed that none of the reviewed blocks provide complete analgesia to the whole breast region alone.²¹

The erector spinae plane block (ESPB) is a novel regional anesthesia technique first described by Forero et al in 2016 as a successful interfascial block for neuropathic pain in the thorax.²⁹ It demonstrated the ability to sufficiently anesthetize unilateral multidermatomal sensation from T1 to L3 when administered at T5.³⁰ When compared with the commonly used PVB in thoracotomies, ESPB showed similar pain relief results with less adverse effects.³¹ In the past 2 years, ESPB has been used in several breast surgeries, such as mastectomies and breast reconstruction.^{32,33} Although several systematic reviews summarize the efficacy and limitations of interfascial regional blocks, none have been conducted for ESPB in breast-related surgeries.

The goal of this study is to systematically review the literature on the efficacy of ESPB in breast surgeries, specifically, mastectomies, lumpectomies, breast augmentations, reductions, and reconstructions. By reviewing the literature, this paper aims to elucidate ESPB's efficacy in breast surgery analgesia, and its potential role in addressing the opioid crisis in North America. It is hoped that this will encourage surgeons to comfortably prescribe less opioids and provide an alternative, safer pain management method for patients.

METHODS

The PUBMED, EMBASE, and Cochrane databases were systematically searched for relevant articles using both keywords and MeSH terms. The specific search strategy used for PUBMED was the following: ("mastectomy" OR "lobectomy" OR "breast" OR "Breast"[Mesh] OR

2

"reduction" OR "augmentation" OR "reconstruction") AND ("erector"). Similar searches were conducted on the 2 other databases.

This systematic review was performed and reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses. Two authors independently reviewed all resulting search entries against the inclusion and exclusion criteria. Any disagreement over the eligibility of an article was adjudicated by an independent researcher. Inclusion criteria consisted of studies that described ESPB in adult females (>18 years) undergoing breast surgery. Due to the novelty of this technique, randomized controlled trials (RCTs), prospective studies, case control studies, and case series/reports were included. Furthermore, there was no lower limit on the number of cases within a study for it to be included. Exclusion criteria composed of articles that exclusively discussed other kinds of regional blocks, and those that discussed ESPB in nonbreast-related surgeries. Finally, commentaries and conference abstracts were excluded.

RESULTS

The primary search yielded 340 articles. Citations were manually checked, and 21 relevant citations were added to the pool of studies. Fifty-nine were excluded as duplicates. The remaining 302 studies' titles and abstracts were independently assessed for inclusion/ exclusion criteria, yielding a total of 50 articles. These articles were fully read, yielding a total of 32 articles to be included in this review.³²⁻⁵² Out of the 32 articles, 6 were RCTs^{34,40,45,51,53,54} and 26 were case reports and case series. All of the articles were published between June 2017 and May 2019 (Fig. 1).

Two RCTs compared ESPB with controls (GA with no regional block),^{33,40} 2 compared ESPB with a PEC,^{34,53} 1 compared it with tumescent anesthesia,⁴⁵ and the final RCT compared 2 groups receiving ESPB with different concentrations of bupivacaine.⁵¹ The sample sizes of the RCTs varied between 38 and 50 female patients of ages 18–70 years. Out of a total of 319 patients included in this review, 259 were participants of these RCTs.

Out of 26 case reports/series, 21 articles discussed the exclusive use of ESPB (continuous and noncontinuous), $\frac{32,33,35,36,39,41,42,44,46,47,49-51,55-57}{5}$ discussed ESPB combined with another method of regional anesthesia [ESPB + PECS, $\frac{38}{5}$ ESPB + selective brachial plexus block, $\frac{39}{5}$ ESPB + transversus thoracic muscle plane block, $\frac{49}{5}$ ESPB + paravertebral nerve block (PVB), $\frac{49}{6}$ ESPB + rhomboid intercostal block + parasternal block $\frac{58}{5}$], and 1 discussed ESPB with the addition of a local anesthetic (liposomal bupivacaine). $\frac{43}{5}$ In total, the case reports and case series comprised 60 patients of ages 20–83 years. The reporting of outcomes was heterogeneous among the RCTs and the case reports/ series. The most common measured outcome was postoperative opioid consumption (n = 23) followed by postoperative pain (n = 22).



PRISMA Flow Diagram

Fig. 1. Search and screening process. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.

Postoperative Opioid Consumption

Postoperative opioid consumption was measured in all 6 RCTs. ESPB, compared with no block, was found to decrease opioid consumption within the first 24 hours post mastectomy as shown by 2 RCTs (P < 0.05).^{40,54} A higher concentration of bupivacaine was associated with less postoperative opioid consumption needed (P = 0.03).⁵¹ Furthermore, ESPB was found to significantly decrease opioid consumption within the first 24 hours post breast reduction when compared with tumescent anesthesia (P< 0.05).⁴⁵ However, both Altiparmak et al and Gad et al showed that patients undergoing unilateral mastectomies who received an ESPB required significantly more tramadol and morphine compared with patients who received a PECS block (P = 0.001 and P < 0.001, respectively).^{34,53} However, it is important to note that both articles used more local anesthetic in the PECS block versus the ESPB (30 cc versus 20 cc) (Table 1).

The benefit of ESPB in reducing postoperative opioid consumption is further seen in the majority of case reports. Seventeen case reports/series measured patients' postoperative opioid consumption. The majority of the patients required no postoperative opioids. No patient required any opioids after postoperative day 4. However, due to the heterogeneity of the opioid type used and the different routes of ingestion (PO versus IV), it is challenging to quantitatively compare postoperative opioid consumption in the different case series.

Postoperative Pain Scores

Pain level was measured using either an NRS or a VAS in all 6 RCTs. When compared with no regional anesthesia (only GA), only 1 RCT found that patients who underwent an ESPB had significantly lower levels of pain at 0, 2, and 4 hours postoperatively (P < 0.05),⁵⁴ whereas the other RCT evidenced no differences in pain between the patients who received ESPB and those who received no regional anesthesia.⁴⁰ Furthermore, Oksuz et al found that patients undergoing ESPB had significantly less postoperative pain compared with tumescent anesthesia (P < 0.0001).⁴⁵ The RCT comparing different concentration of bupivacaine in ESPB showed that patients who received the higher concentration of 0.375% had significantly less pain levels at every measured time point (P < 0.05).⁵¹ Finally, the 2 RCTs that compared ESPB with a PECS block found that patients undergoing the former block had higher levels of pain in the first 24 hours postoperatively (P < 0.05).^{34,53} Pain scores were further mentioned in 16 case reports, most of which (15 out of 16) reported the mean pain scores to be less than 5 on the VAS or NRS during the first 24 hours postoperatively. The maximum pain score reported by 1 patient was 6.43 Postoperative rescue analgesia was provided to patients with an NRS of 4 or higher.

Postoperative Symptoms of Nausea/Vomiting

Symptoms of nausea and vomiting were measured in 4 of the 6 RCTs. Patients who received ESPB were found to have significantly less complaints of postoperative symptoms of nausea/vomiting (PONV) when compared with those who received tumescent anesthesia (P < 0.005).⁴⁵ Although there was no significant difference between patients who received ESPB and those who received no regional anesthesia (P = 0.768) in 1 of the studies,⁴⁰ another showed that 5 of 20 control patients in comparison

References	No. Patients	Age of Patients	Type of Surgery	Groups	Opioid Consumption per Milligram at 24 h Postoperatively
Altiparmak et al ⁵¹	41	38–70	Unilateral radical mastectomy with axillary lymph node dissection	(1)ESPB 0.375% bupivacaine (2)ESPB 0.25% bupivacaine	149.5 versus 199.5*
Altiparmak et al (2018) ³⁴	38	18-70	Unilateral radical mastectomy	(1)ESPB (2)PECS	196 versus 132.78*
Gad et al ⁵⁸	47	18-65	Unilateral modified radical mastectomy	(1)ESPB (2)PECS	16.7 versus 10.7*
Gurkan et al (2018) ⁴⁰	50	25–65	 (1) Modified radical mastectomy (2) Simple mastectomy (3) Lumpectomy + sentinel lymph node biopsy (4) Lumpectomy + axillary dissection 	(3)ESPB (4)No intervention	5.76 versus 16.6*
Oksuz et al (2018) ⁴⁵	43	18–70	Breast reduction surgery	(1)ESPB (2)Tumescent anesthesia	0.9 versus 2.09*
Singh et al ⁵⁴	40	20–55	Modified radical mastectomy	(1)ESPB (2)No intervention	1.95 versus 9.3*

Table 1. Opioid Consumption at 24 h Postoperatively as Measured in Included RCTs

* denotes statistically significant difference set at P<0.05.

with none of the ESPB patients required rescue metoclopramide for severe PONV.⁵⁴ Furthermore, a higher concentration of bupivacaine was not shown to affect PONV, as demonstrated by Altiparmak et al⁵¹ One case series on 2 patients measured PONV and simply stated that no PONV was observed.⁵⁹

Intraoperative Opioid Requirement

Intraoperative opioid requirement due to pain response was measured in 2 of the 6 RCTs. The mean fentanyl requirement was found to be similar in both groups that were administered ESPB with different bupivacaine concentrations (P = 0.289).⁵¹ Furthermore, Gad et al found that there was no difference in the mean intraoperative fentanyl requirements between patients who underwent an ESPB compared with a PECS.⁵³ Only 5 case series/reports discussed the use of intraoperative opioid requirement for pain response.^{34,46} Talawar et al found that 6 of 10 patients receiving ESPB required additional intraoperative fentanyl.⁴⁶ Two other case reports mentioned the use of 150⁵⁸ and 100 µg⁶⁰ of fentanyl intraoperatively. On the other hand, Altiparmak et al and Kim et al reported that no additional intraoperative opioids were required for patients on ESPB.^{34,61}

Other Outcomes

The other outcomes reported include patient satisfaction, hospital length of stay, quality of sleep, and cortisol and prolactin levels. Two RCTs reported patient satisfaction.^{45,54} Patient satisfaction was reported to be better in the ESPB group compared with the control group of no regional anesthesia (P < 0.0001), and the tumescent anesthesia group (P < 0.001). Furthermore, 1 of the case reports mentioned patient satisfaction by stating that the patient was overall satisfied with the block. The case report failed to mention what test was used to measure satisfaction.⁶¹ The lengths of hospital stay of only 4 patients were reported, all of which varied between 8 hours and 3 days. However, due to the heterogeneity of the breast surgeries performed, no meaningful conclusion about length of hospital stay associated with ESPB should be drawn.^{35– 37,61} Only 1 case report measured patient sleep quality and mentioned no postoperative insomnia.⁵⁰ Prolactin and cortisol levels were measured in only 1 RCT which found no difference in either levels between patients who underwent ESPB and those who underwent a PECS block. However, both groups evidenced a significant decrease in both hormones 24 hours postoperatively.⁵³

Complications of ESPB

Only 2 articles (3 cases in total) reported complications. Ueshima and Otake reported 2 cases where there was inadequate intraoperative analgesic effect of the ESBP on T2–T6 intercostal nerves when assessed 20-minute postblock administration.⁴⁸ Only 1 major complication was recorded in a patient with a pneumothorax 3 minutes after the administration of ESPB.⁶²

DISCUSSION

The present systematic review elucidates the potential benefits of ESPB in breast surgeries. All of the RCTs demonstrated positive efficacy of ESPB. As an adjunct to general anesthesia, it is found to be superior in decreasing postoperative pain and opioid consumption in patients undergoing mastectomies. When compared with tumescent anesthesia, ESPB was associated with less postoperative pain, opioid consumption, and overall greater patient satisfaction post breast reduction.⁴⁵ Although PECS block was superior to ESPB block in terms of postoperative pain and opioid consumption, the authors of this review believe that ESPB is still a suitable option for breast surgeries especially due to the ease and safety of administration and the higher risk of complications associated with PECS blocks.^{34,53}

Furthermore, different concentrations of local anesthetic agents, along with differences in patient positioning, can have varied clinical effects. Administration of ESPB using a higher concentration of local anesthetic

can lead to stronger effects, as seen by Altiparmak et al, where 0.375%, compared with 0.25% of bupivacaine, had a superior outcome in reducing postoperative opioid consumption. Moreover, the position of the patient is known to affect the diffusion of the anesthetic agent. Although Forero et al originally described the technique to be administered whereas the patient is seated,²⁹ Ueshima and Otake showed that the block still provided adequate breast analgesia when administrated in the lateral decubitus position, which allows the patient to be under general anesthesia before administration of the block.49 Aygun et al further demonstrated successful administration of ESPB via the "Dry Leaf technique" that allows the patient to be in the supine position. This permits administration of the block after commencement of the surgery.⁶³ All 32 articles included in this review performed ESPB as described by Forero et al, but with slight modifications to the technique regarding position of patient (sitting/lateral decubitus/ prone/supine), spine level of injection (T2–T5), and local anesthetic used (Table 2).

Adequate regional block anesthesia can potentially allow patients to avoid general anesthesia which would decrease perioperative complications.⁶⁴ In fact, several case reports showed successful breast operations using ESPB with sedation, without the use of general anesthesia.^{37,38,42,61} This is very promising as it allows high-risk patients with cardiac comorbidities and older patients to undergo breast surgeries whereas avoiding potential complications associated with general anesthesia.

A major limitation to the use of any regional block in breast surgery is the complex innervation of the region and the potential for block failure. The vast majority of the studies did not assess the sensory analgesia via pinprick/ice sensation testing, and therefore potential failures were left undetected. Four studies reported the need for intraoperative fentanyl use due to augmented pain response which could indicate inadequacy of ESPB. 46,51,58,60 One case series reported 2 patients for which the block failed and an adjunctive block had to be administered.48 Several reports opted to combine ESPB with another block to achieve complete anesthesia of the breast and axilla region. Another limitation of regional blocks, including ESPB is their duration of action, which is limited to 12-24 hours with traditional local anesthetics.⁴³ However, Kumar et al was able to prolong the analgesic effect of ESPB to over 72 hours with the addition of liposomal bupivaine.⁴³

ESPB is an easy-to-administer block because of the simple identification of anatomic landmarks on ultrasound⁶⁵

SittingFinneran IV et al (2017)T3 T2 and T420-mL 0.5% ropivacaine with 2.5-µg/mL epinephrineDe Cassai et al standT2 and T415-mL 0.5% ropivacaine with 2.5-µg/mL epinephrineAltiparmak et al standT4T415-mL 0.5% ropivacaine with 2.5-µg/mL epinephrineOksuz et al (2018) standT4T4Nair et al standT525-mL 0.25% bupivacaineDe Cassai et al standT525-mL 0.25% bupivacaineDe Cassai et al standT525-mL 0.25% bupivacaineSingh et al stand20-mL 0.5% ropivacaine20-mL 0.5% ropivacaineSingh et al stand20-mL 0.5% ropivacaine20-mL 0.5% ropivacaineBonvicini et al stand20-mL 0.5% ropivacaine20-mL 0.5% bupivacaineKumar et al stand20-mL 0.5% ropivacaine20-mL 0.5% bupivacaineKumar et al stand20-mL 0.5% ropivacaine20-mL 0.5% bupivacaineBonvicini et al stand25-mL 0.25% bupivacaine25-mL 0.25% bupivacaineKumach et al standT420-mL 0.5% ropivacaine and 26-mg mepivacaine)LateralUeshimaT4UeshimaT520-mL 0.5% ropivacaine and 26-mg mepivacaine)LateralUeshimaT4Altiparmak et al (2018) standT4Jain et al standT4Ohgoshi et al standT5Ueshima and OtakeT5Ongoshi et al standT6Ueshima and OtakeT6Ongoshi et al standT6Dordo stand20-mL 0.25% bupivacaine et and b-mg bupivacaineOhgoshi et al standT6 <th>Patient Position</th> <th>References</th> <th>Injection Level</th> <th>Anesthetic</th>	Patient Position	References	Injection Level	Anesthetic
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Sitting	Finneran IV et al (2017) ³⁹	Т3	20-mL 0.5% ropivacaine with 2.5-µg/mL epinephrine
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	0		T2 and T4	15-mL 0.5% ropivacaine with 2.5-µg/mL epinephrine
Altiparmak et al20-mL 0.375% bupivacaine versusOksuz et al (2018)*620-mL 0.25% bupivacaineNair et al*130-mL 0.25% bupivacaineVersima and Otake*8T5De Cassai et al*220-mL 0.25% bupivacaineSingh et al*320-mL 0.57% bupivacaineSingh et al*420-mL 0.57% bupivacaineBorycini et al*420-mL 0.57% bupivacaineBorycini et al*420-mL 0.57% bupivacaineBorycini et al*420-mL 0.57% bupivacaineBorycini et al*425-mL 0.25% bupivacaineBorycini et al*525-mL 0.25% bupivacaineBorycini et al*625-mL 0.25% bupivacaineVeiga et al*674Borycini et al*620-mL 0.25% levobupivacaineVeiga et al*674Ueshima*620-mL 0.25% levobupivacaine + 0.5-µg /kg dexmedtomidineVeiga et al*675Ueshima*620-mL 0.25% levobupivacaineUeshima*620-mL 0.25% levobupivacaineVersion et al*620-mL 0.25% levobupivacaineVeiga et al*675Ohgoshi et al*675Ohgoshi et al*675Ohgoshi et al*620-mL 0.25% bupivacaineUeshima and Otake*676Orozco et al*776ProneColores*7ProneColores*7ProneColores*7Ohgoshi et al*674<		De Cassai et al ³⁸	T4	20-mL 0.5% ropivacaine with epinephrine
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		Altiparmak et al ^{51,52}		20-mL 0.375% bupivacaine versus
Oksuz et al (2018)**20-mL 0.25% bupivacaineNair et al **30-mL 0.25% bupivacaineUeshima and Otake**T5De Cassai et al**20-mL 0.5% topivacaineSingh et al**20-mL 0.5% bupivacaineSingh et al**20-mL 0.5% bupivacaineSingh et al**20-mL 0.5% bupivacaineBonvicini et al**20-mL 0.5% bupivacaineBonvicini et al**20-mL 0.25% bupivacaineBonvicini et al**20-mL 0.25% bupivacaineBonvicini et al**25-mL 0.25% bupivacaineBonvicini et al**25-mL 0.25% bupivacaine and 266-mg liposomal bupivacaineBonvicini et al**25-mL 0.25% bupivacaine and 266-mg liposomal bupivacaineBonvicini et al**25-mL 0.5% pupivacaine and 266-mg liposomal bupivacaineBonvicini et al**25-mL 0.5% pupivacaine and 20-mg mepivacaineBonvicini et al**25-mL 0.5% pupivacaine and 20-mg mepivacaineBonvicini et al**20-mL 0.25% levobupivacaineBonvicini et al**20-mL 0.25% levobupivacaineBonvicini et al**20-mL 0.25% pupivacaine with epinephrineBonvicini et al**20-mL 0.25% levobupivacaineBonvicini et al**20-mL 0.25% lopolupivacaineBonvicini et al**20-mL 0.25% lopolupivacaine per sideBonvicini et al**20-mL 0.25% lopolupivacaineBonvicini et al**20-mL 0.25% lopipvacaine </td <td></td> <td></td> <td></td> <td>20-mL 0.25% bupivacaine</td>				20-mL 0.25% bupivacaine
Nair et al30-mL 0.25% bupyracameUeshima and OtakeT5De Cassai et al25-mL 0.25% bupyracaineSingh et al25-mL 0.25% bupyracaineSingh et al25-mL 0.25% bupyracaineAltiparmak et al (2018)25-mL 0.25% bupyracaineBonvicini et al25-mL 0.25% bupyracaineCad et al25-mL 0.25% levobupivracaineUeshima20-mL 0.25% levobupivracaineUeshima20-mL 0.5% ropivacaine with epinephrineBonvicini et al20-mL 0.5% ropivacaineUeshima20-mL 0.5% ropivacaineSelvi and Tulgar25-mL 0.5% levobupivacaineKimachi et al20-mL 0.5% ropivacaineBonvicini et al20-mL 0.25% bupivacaineBonvicini et al20-mL 0.25% bupivacai		Oksuz et al $(2018)^{45}$		20-mL 0.25% bupivacaine
Use Shima and Otake**1525-mL0.5% ropivacaineDe Cassai et al**20-mL0.5% ropivacaineSingh et al**20-mL0.5% bupivacaineSingh et al**20-mL0.5% bupivacaineAltiparmak et al (2018)**25-mL0.5% bupivacaineBonvicini et al**25-mL0.5% bupivacaineBonvicini et al**25-mL0.5% bupivacaineBonvicini et al**25-mL0.5% bupivacaine and 266-mg iposomal bupivacaineVeiga et al**20-mL0.5% levobupivacaineBonvicini et al**25-mL0.5% levobupivacaineCade et al**7420-mL0.5% ropivacaine and 20-mg mepivacaine)LateralGad et al**7420-mL0.5% levobupivacaine + 0.5-gu/s (g dexmedetomidinedecubitusKim et al**7520-mL0.5% ropivacaine with epinephrineWeiga et al**7520-mL0.5% ropivacaine with epinephrineUeshima**7520-mL0.5% ropivacaine with epinephrine and 8-mg dexamethasoneKwon et al**7520-mL0.5% ropivacaine with epinephrineJain et al**7520-mL0.5% ropivacaineOhgoshi et al**7520-mL0.5% ropivacaineJain et al**7520-mL0.5% ropivacaineUeshima and Otake**7620-mL0.5% ropivacaineOrazo et al**7620-mL0.5% ropivacaineDispertative infusion:0.25% levobupivacaine20-mLOrazo et al**7620-mL0.5% ropivacaineOrazo		Nair et al ⁴⁴	T۲	30-mL 0.25% bupivacaine
De Cassal et al25-mL 0.25% bupivacaineSingh et al20-mL 0.25% bupivacaineTalawar et al (2018)20-mL 0.375% ropivacaineAltiparmak et al (2018)25-mL 0.25% bupivacaineBonvicini et al25-mL 0.25% bupivacaine and 16-mg mepivacaine)Kumar et al25-mL 0.25% bupivacaine and 206-mg liposomal bupivacaineBonvicini et al25-mL 0.25% bupivacaine and 20-mg mepivacaine)LateralGad et alGad et al74Ueshima20-mL 0.5% ropivacaine with epinephrineUeshima20-mL 0.5% ropivacaine with epinephrineUeshima20-mL 0.25% levobupivacaineScivi and Tulgar7420-mL 0.25% levobupivacaine + 0.5-ng /kg dexmedetomidine25-mL 0.25% levobupivacaine + 0.5-ng /kg dexmedetomidine25-mL 0.25% levobupivacaine + 0.5-ng /kg dexmedetomidine25-mL 0.25% levobupivacaine + 0.5-ng /kg dexmedetomidine20-mL 0.25% levobupivacaineUeshimaJain et alJain et alUeshima and OtakeUeshima and OtakeOroze ot elTranaka et alVerigeTorneOroze ot elTranaka et alVerigeTranaka et alVerigeTranaka et alOroze ot elTranaka et alOroze ot elTranaka et alOroze ot elTranaka et al <td></td> <td>De Cessoi et al³⁸</td> <td>15</td> <td>25-mL 0.25% levobupivacaine</td>		De Cessoi et al ³⁸	15	25-mL 0.25% levobupivacaine
Singh et al Singh et al Talawar et al (2018)20-mil 0.5% bupivacaine 20-mil 0.5% bupivacaineAltiparmak et al (2018)20-mil 0.5% bupivacaineAltiparmak et al (2018)20-mil 0.5% bupivacaineBonvicini et al Veiga et al20-mil 0.5% bupivacaine and 266-mg liposomal bupivacaineBonvicini et al Bonvicini et al decubitus20-mil 0.5% bupivacaineBonvicini et al decubitus20-mil 0.5% bupivacaine and 20-mg mepivacaine)Lateral decubitus20-mil 0.5% bupivacaine and 20-mg mepivacaine)Lateral 		Singh et al ³³		20-III. 0.5% hunivacaine
Jalavar et al (2018) **20-mL 0.375% ropivacaineAltiparmak et al (2018) **20-mL 0.375% ropivacaineBonvicini et al**25-mL 0.25% bupivacaine and 16-mg mepivacaine)Kumar et al **25-mL 0.25% bupivacaine and 260-mg liposomal bupivacaineVeiga et al **25-mL 0.25% levobupivacaine and 20-mg mepivacaine)LateralGad et al **decubitusKim et al **Ueshima**T4Ueshima**T4Ueshima**T5Selvi and Tulgar**T5Kwon et al**20-mL 0.25% levobupivacaineJain et al**T5Jain et al**T5Ueshima and Otake**20-mL 0.25% bupivacaineUeshima and Otake**76Ohgoshi et al**20-mL 0.25% levobupivacaineLuteralGad et al**Altiparmak et al (2018)**20-mL 0.25% levobupivacaineJain et al**T5Ueshima and Otake**76Ohgoshi et al**T6Ongo co et al**76Ongo co et al**T6Ournu0.25% levobupivacaineProneGurka et al (2018) **SupineAygun et al**TorneT4Ournu0.25% levolopivacaineYou co et al**T6Ournu0.25% bupivacaineYou co et al**T6Ournu0.25% bupivacaineYou co et al**T6You co et al**T6You co et al**T6You co et al**T6You co et al**T3/T4You co et al**T3/		Singh et al ⁵⁴		20-mL 0.5% hupivacaine
Altiparmak et al (2018) \$425-mL 0.25% bupivacaineBonvicini et al \$623-mL (75-mg ropivacaine and 266-mg liposomal bupivacaineKumar et al \$625-mL 0.25% bupivacaine and 266-mg liposomal bupivacaineVeiga et al \$625-mL 0.25% levobupivacaine and 206-mg mepivacaine)LateralGad et al \$5T4decubitusGad et al \$5T4Ueshima \$6^{62}\$25-mL 0.25% levobupivacaine with epinephrineUeshima \$6^{62}\$20-mL 0.25% levobupivacaineUeshima \$6^{62}\$20-mL 0.25% levobupivacaineUeshima \$6^{62}\$20-mL 0.25% levobupivacaineKimachi et al \$10^{62}\$20-mL 0.25% levobupivacaineKimachi et al \$10^{62}\$20-mL 0.25% levobupivacaineJain et al \$10^{62}\$20-mL 0.25% levobupivacaineAltiparmak et al (2018) \$420-mL 0.25% levobupivacaineJain et al \$10^{62}\$20-mL 0.25% bupivacaineUeshima and Otake \$10^{62}\$20-mL 0.25% bupivacaineOhgoshi et al \$12^{62}\$76Ueshima and Otake \$10^{63}\$76ProneGut et al \$12^{63}\$ProneGut et al \$10^{63}\$Ueshima and Otake \$10^{63}\$74Ohgoshi et al \$12^{63}\$74Ohgoshi et al \$12^{63}\$76Ongo and Otake \$10^{63}\$76Orozo et al \$12^{63}\$76Opine74Opine0.25% levobupivacaineOrozo et al \$12^{63}\$74Opine73/T4Opine73/T4Opine73/T4Opine73/T4Opine73/T4		Talawar et al $(2018)^{46}$		20-mL 0.375% ronivacaine
Bonvicini et al23-mL (75-mg ropivacaine and 266-mg liposomal bupivacaineKumar et al25-mL 0.55% bupivacaine and 206-mg liposomal bupivacaineVeiga et al25-mL 0.55% levobupivacaineBonvicini et al74Cad et al74Cad et al74Ueshima20-mL 0.55% levobupivacaineUeshima20-mL 0.25% levobupivacaineSelvi and Tulgar75Kimachi et al75More et al20-mL 0.25% levobupivacaineKimachi et al75Obgoshi et al75Ohgoshi et al20-mL 0.25% bupivacaineJain et al2018Ueshima and Otake20-mL 0.25% bupivacaineOrozo et al75Orozo et al76Opore durat et al20-mL 0.25% bupivacaineVeiga et al75Ongoshi et al7620-mL 0.25% bupivacaineProneGurka et alGurka et al76Oporo et al76Oporo et al76Oporo et al76Oporo et al76Ourle Durat et al76Ourle Durat et al76Obligoshi et al76Obligoshi et al76Ourle Durat et al76Ourle Durat et al76Ourle Durat et al76Ourle Durat et al		Altiparmak et al $(2018)^{34}$		25-mL 0.25% bupivacaine
Kumar et al25-mL 0.25% bujivacaine and 266-mg liposomal bupivacaine 20-mL 0.5% levobupivacaine 25-mL (75-mg ropivacaine and 20-mg mepivacaine)Lateral decubitusGad et al25-mL (75-mg ropivacaine and 20-mg mepivacaine) 25-mL (75-mg ropivacaine and 20-mg mepivacaine)Lateral decubitusGad et al1420-mL 0.25% levobupivacaine and 20-mg mepivacaine) 25-mL (75-mg ropivacaine with epinephrine 20-mL 0.25% levobupivacaine + 0.5-µg/kg dexmedetomidine 20-mL 0.5% ropivacaine with epinephrine at 20 mL/8 h for 48 hUeshimaUeshima20-mL 0.25% levobupivacaine 20-mL 0.25% levobupivacaineUeshimaUeshima20-mL 0.25% levobupivacaine 20-mL 0.25% levobupivacaine 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine 30-mL 0.375% ropivacaine with epinephrine and 8-mg dexamethasone 30-mL 0.375% ropivacaine with epinephrine Postoperative infusion: bolus of 30-mL 0.375% ropivacaine with epinephrine Postoperative infusion: 0.25% bupivacaine at 5-mL/h for 72 h 20-mL 0.25% bupivacaineAltiparmak et al (2018)20-mL 0.25% levobupivacaine 20-mL 0.25% bupivacaine Postoperative infusion: 0.25% bupivacaine at 8 mL/h 20-mL 0.375% ropivacaine Postoperative infusion: 0.2% ropivacaine at 8 mL/h 20-mL 0.375% levobupivacaine Postoperative infusion: 0.2% bupivacaine at 20 mL/8h for 48 h 30-mL 0.25% bupivacaine Postoperative infusion: 0.2% levobupivacaine at 20 mL/8h for 48 h 30-mL 0.25% bupivacaineUeshima and Otake7620-mL 0.25% bupivacaine Postoperative infusion: 0.2% propivacaine at 8 mL/h 20-mL 0.375% levobupivacaineUeshima and Otake7620-mL 0.25% bupivacaine Postoperative infusion: 0.2% bupivacaine with epinephrine + 0.5% lidocaine 20-mL 0.25% bupivacaine <t< td=""><td></td><td>Bonvicini et al³⁶</td><td></td><td>23-mL (75-mg ropivacaine and 16-mg mepivacaine)</td></t<>		Bonvicini et al ³⁶		23-mL (75-mg ropivacaine and 16-mg mepivacaine)
Veiga et al ⁵⁰ Bonvicini et al ⁵⁰ 20-mL 0.5% levobupivacaine 25-mL (75-mg ropivacaine and 20-mg mepivacaine)Lateral decubitusGad et al ⁵⁵ Kim et al ⁶¹ T4 20-mL 0.25% levobupivacaine + 0.5-µg/kg dexmedetomidine 20-mL 0.25% levobupivacaine with epinephrine Postoperative infusion: 0.375% ropivacaine with epinephrine at 20 mL/8 h for 48 hUeshima ⁶² Ueshima ⁶⁹ Selvi and Tulgar ⁶⁰ Kimachi et al ¹⁶ T5 20-mL 0.25% levobupivacaine + 5-mL 0.5% lidocaine per side 20-mL 0.5% ropivacaine with epinephrine and 8-mg dexamethasone 30-mL 0.375% ropivacaine with epinephrine Postoperative infusion: 0.375% ropivacaine with epinephrine every 12 h for 48 h 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine at 5-mL/h for 72 h 20-mL 0.375% ropivacaine at 8 mL/h 20-mL 0.375% ropivacaine at 8 mL/h 20-mL 0.375% ropivacaine Postoperative infusion: 0.2% levobupivacaine at 8 mL/h 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine at 20 mL/8h for 48 h 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine at 20 mL/8h for 48 h 20-mL 0.25% bupivacaine at 8 mL/h 20-mL 0.375% ropivacaine at 8 mL/h 20-mL 0.375% ropivacaine at 8 mL/h 20-mL 0.375% levobupivacaine at 20 mL/8h for 48 h 30-mL 0.25% bupivacaine at 20 mL/8h for 48 h 30-mL 0.25% bupivacaine at 8 mL/h 20-mL 0.375% levobupivacaine at 20 mL/8h for 48 h 30-mL 0.25% bupivacaine at 20 mL/8h for 48 h <br< td=""><td></td><td>Kumar et al⁴³</td><td></td><td>25-mL 0.25% bupivacaine and 266-mg liposomal bupivacaine</td></br<>		Kumar et al ⁴³		25-mL 0.25% bupivacaine and 266-mg liposomal bupivacaine
Bonvicini et al ³⁵ Lateral Gad et al ³⁵ T4 20-mL $(75$ -mg ropivacaine and 20 -mg mepivacaine) Lateral Gad et al ³⁵ T4 20-mL 0.25% levobupivacaine $+ 0.5$ -µg/kg dexmedetomidine 20-mL $0.25%$ levobupivacaine with epinephrine Postoperative infusion: 0.375% ropivacaine with epinephrine at 20 mL/8 h for 48 h 20-mL 0.25% levobupivacaine $+ 5$ -mL 0.5% lidocaine per side Selvi and Tulgar ⁶⁰ Kimachi et al ³² T5 20-mL 0.5% ropivacaine with epinephrine and 8-mg dexamethasone Kimachi et al ³² T5 20-mL 0.5% ropivacaine with epinephrine and 8-mg dexamethasone Selvi and Tulgar ⁶⁰ Kimachi et al ³² T5 20-mL 0.5% ropivacaine with epinephrine and 8-mg dexamethasone Altiparmak et al (2018) ³⁴ 20-mL 0.25% bupivacaine Jain et al ⁴¹ 20-mL 0.25% bupivacaine Dostoperative infusion: 0.375% ropivacaine at 5 -mL/h for 72 h 20-mL 0.375% ropivacaine at 8 -mL/h Postoperative infusion: 0.2% ropivacaine at 8 -mL/h for 72 h 20-mL 0.375% levobupivacaine Postoperative infusion: 0.2% ropivacaine at 8 -mL/h for 72 h 20-mL 0.375% levobupivacaine Postoperative infusion: 0.2% ropivacaine at 8 -mL/h 20-mL $0.375%$ levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 -mL/8h for 48 h 30-mL $0.25%$ levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 -mL/8h for 48 h 30-mL $0.25%$ levobupivacaine Postoperative infusion: 0.2% ropivacaine at 20 -mL/8h for 48 h 30-mL $0.25%$ levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 -mL/8h for 48 h 30-mL $0.25%$ levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 -mL/8h for 48 h 30-mL $0.25%$ levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 -mL/8h for 48 h 30-mL $0.25%$ levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 -mL/8h for 48 h 30-mL $0.25%$ levobupivacaine Postoperative infusion: 0.1% levobupivacaine interperime $+ 0.5\%$ lidocaine $+ 7.5$ -mL 2% lidocaine $+ 7.5$ -mL 2% lidocaine $+ 7.5$ -m		Veiga et al ⁵⁰		20-mL 0.5% levobupivacaine
Lateral decubitusGad et al ⁵³ T420-mL 0.25% levobupivacaine + 0.5-µg/kg dexmedetomidine 20-mL 0.25% levobupivacaine + 0.5-µg/kg dexmedetomidine 20-mL 0.5% ropivacaine with epinephrine Postoperative infusion: 0.375% ropivacaine with epinephrine at 20 mL/8 h for 48 hdecubitusUeshima ⁶² Ueshima ⁶⁹ Selvi and Tulgar ⁶⁰ Kimachi et al ¹² 20-mL 0.25% levobupivacaine Single injection, bilateral infusion: 20-mL 0.25% levobupivacaine per side 20-mL 0.25% lopivacaine with epinephrine and 8-mg dexamethasone 30-mL 0.375% ropivacaine with epinephrine and 8-mg dexamethasone 30-mL 0.375% ropivacaine with epinephrine Postoperative infusion: bolus of 30-mL 0.375% ropivacaine with epinephrine every 12 h for 48 h 20-mL 0.25% bupivacaineAltiparmak et al (2018) ⁵⁴ Jain et al ⁴¹ 20-mL 0.25% bupivacaine 20-mL 0.375% ropivacaine at 8 mL/h 20-mL 0.25% levobupivacaine 20-mL 0.25% bupivacaine 20-mL 0.25% levobupivacaine 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaineProneGurkan et al (2018) ⁴⁰ T4T420-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaineProneGurkan et al (2018) ⁴⁰ T4ProneGurkan et al (2018) ⁴⁰ T4Prone <td></td> <td>Bonvicini et al³⁵</td> <td></td> <td>25-mL (75-mg ropivacaine and 20-mg mepivacaine)</td>		Bonvicini et al ³⁵		25-mL (75-mg ropivacaine and 20-mg mepivacaine)
decubitusKim et al20-mL 0.5% ropivacaine with epinephrine Postoperative infusion: 0.375% ropivacaine with epinephrine at lock for 48 hUeshima ⁶² Ueshima ⁷⁰ Kimachi et al20-mL 0.25% levobupivacaine Selvi and Tulgar ⁶⁰ Kimachi et al ¹⁶² T5Kwon et al ⁵⁶ 7575Altiparmak et al (2018) ³⁴ Jain et al ⁴¹ 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine0.375% ropivacaine with epinephrine and 8-mg dexamethasone 30-mL 0.375% ropivacaine with epinephrine Postoperative infusion: 0.25% bupivacaine 20-mL 0.25% bupivacaineOhgoshi et al ³² 0.4020-mL 0.25% bupivacaine 20-mL 0.25% bupivacaineDostoperative infusion: 0.25% bupivacaine 20-mL 0.25% bupivacaine20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaineOhgoshi et al ³² 0.375% ropivacaine 20-mL 0.25% bupivacaineProne Gurkan et al (2018) ⁴⁰ T6 T4 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine<	Lateral	Gad et al	Τ4	20-mL 0.25% levobupivacaine + 0.5-µg/kg dexmedetomidine
Postoperative infusion: 0.375% ropivacaine with epinephrine at 20mL/8 h for 48 h 20-mL 0.25% levobupivacaine Selvi and Tulgar ⁶⁰ Kimachi et al ¹² T5 Kwon et al ⁵⁶ T5 Altiparmak et al (2018) ³⁴ Jain et al ⁴¹ 20-mL 0.25% bupivacaine with epinephrine Jain et al ⁴¹ 20-mL 0.25% bupivacaine Ohgoshi et al ³² Postoperative infusion: 0.25% bupivacaine at 5-mL/h for 72 h 20-mL 0.25% bupivacaine Postoperative infusion: 0.25% bupivacaine at 5-mL/h for 72 h 20-mL 0.375% ropivacaine Postoperative infusion: 0.25% bupivacaine at 5-mL/h for 72 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.25% bupivacaine at 8 mL/h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.25% bupivacaine at 8 mL/h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20mL/8 h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.25% bupivacaine at 8 mL/h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.25% bupivacaine at 20mL/8 h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.25% bupivacaine at 20mL/8 h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.25% bupivacaine at 20mL/8 h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.25% bupivacaine at 20mL/8 h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.25% bupivacaine at 20mL/8 h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20mL/8 h for 48 h 30-mL 0.25% bupivacaine Postoperative infusion: 0.1% levobupivacaine at 20mL/8 h for 48 h 30-mL 0.25% bupivacaine Postoperative infusion: 0.1% levobupivacaine at 20mL/8 h for 48 h 30-mL 0.25% bupivacaine with epinephrine + 0.5% lidocaine Postoperative infusion: 0.1% levobupivacaine + 7.5-mL 2% lidocaine + 7.5-mL	decubitus	Kim et al		20-mL 0.5% ropivacaine with epinephrine
Ueshima ⁶² Ueshima ⁵⁹ 20-mL 0.25% levobupivacaine Selvi and Tulgar ⁶⁰ Kimachi et al ¹⁶² 20-mL 0.25% levobupivacaine single injection, bilateral infusion: 20-mL 0.25% bupivacaine + 5-mL 0.5% lidocaine per side 20-mL mixture of 10-mL 0.25% bupivacaine + 5-mL 0.5% lidocaine per side 20-mL mixture of 10-mL 0.25% bupivacaine + 5-mL 0.5% lidocaine per side 20-mL 0.375% ropivacaine with epinephrine and 8-mg dexamethasone 30-mL 0.375% ropivacaine with epinephrine Postoperative infusion: bolus of 30-mL 0.375% ropivacaine with epinephrine every 12 h for 48 h 20-mL 0.25% bupivacaineAltiparmak et al (2018) ³⁴ Jain et al ⁴¹ 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine Postoperative infusion: 0.25% bupivacaine at 5-mL/h for 72 h 20-mL 0.375% ropivacaine Postoperative infusion: 0.25% bupivacaine at 8 mL/h 20-mL 0.375% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8h for 48 h 30-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8h for 48 h 30-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine + 7.5-mL 2% lidocaine + 7.5-mL 2% lidocaine + 7.5-mL 2% lidocaine + 7.5-mL				Postoperative infusion: 0.375% ropivacaine with epinephrine at 20 mL/8 h
Ueshima**20-mL 0.25% levolupivacaineUeshima**Selvi and Tulgar**Selvi and Tulgar**T5Selvi and Tulgar**T5Kimachi et al**T5Kwon et al**Some tal**Altiparmak et al (2018)**Some tal**Jain et al**20-mL 0.5% ropivacaine with epinephrineOhgoshi et al**20-mL 0.25% bupivacaineUeshima and Otake**00-mL 0.25% levolupivacaineOrozco et al**T6ProneGurkan et al (2018)**SupineAygun et al**TormeSurfarSupineAygun et al**TormeT3/T4SupineAygun et al**TormeT3/T4TormeT3/T4TormeSurfarTormeT3/T4TormeTaranaka et al**TormeT3/T4TormeT3/T4TormeT3/T4TormeTaranaka et al**TormeT3/T4TormeTaranaka et al**TormeT3/T4TormeT3/T4TormeT3/T4TormeTaranaka et al**TormeTaranaka et al**Torme<		U ashima 62		for 48 h
Selvi and Tulgar60Solvi		Ueshima ⁵⁹		20-IIIL 0.25% levolupivacalle Single injection, biloteral infusion, 90 mL 0.95% levolupivacaine per side
Sector and FungationTo20 mL 0.15% ropivacaine with epinephrine and 8-mg dexamethasoneKimachi et all?T520 mL 0.375% ropivacaine with epinephrineKwon et al ⁵⁶ 30 mL 0.375% ropivacaine with epinephrineAltiparmak et al (2018) ³⁴ 20 mL 0.25% bupivacaineJain et al ⁴¹ 20 mL 0.25% bupivacaineOhgoshi et al ⁵² 20 mL 0.25% bupivacaineTanaka et al ⁴⁷ 20 mL 0.375% ropivacaine at 5 mL/h for 72 hUeshima and Otake ⁴⁹ 0 rotoco et al ⁵⁷ Orozco et al ⁵⁷ T6ProneGurkan et al (2018) ⁴⁰ SupineAygun et al ⁶³ T3/T430 mL 0.25% bupivacaineCorne L al ⁵³ T3/T4Corne L al ⁵⁴ T3/T4Corne L al ⁵⁵ T5Corne L al ⁵⁶ T3/T4Corne L al ⁵⁶ T3/T4Corne L al ⁵⁶ T3/T4Corne L al ⁵⁷ T6Corne L al ⁵⁶ T3/T4Corne L al ⁵⁶ T3/T4Corne L al ⁵⁶ T3/T4Corne L al ⁵⁷ T6Corne L al ⁵⁶ T3/T4Corne L al ⁵⁷ T6Corne L al ⁵⁶ T3/T4Corne L al ⁵⁶ T3/T4Corne L al ⁵⁷ T6Corne L al ⁵⁶ T3/T4Corne L al ⁵⁶ T3/T4Corne L al ⁵⁷ T6Corne L al ⁵⁶ Corne L al ⁵⁶ T3/T4Corne L al ⁵⁶ Corne L al ⁵		Selvi and Tulgar ⁶⁰		20 mL mixture of 10 mL 0.25% hunivacaine + 5 mL 0.5% lidocaine per side
Kind et allFo<		Kimachi et al ⁴²	Т5	20-mL 0.5% ropiyacaine with epinephrine and 8-mg devamethasone
Postoperative infusion: bolus of 30-mL 0.375% ropivacaine with epinephrine every 12 h for 48 h 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine at 5-mL/h for 72 h 20-mL 0.375% ropivacaine 20-mL 0.25% bupivacaine Postoperative infusion: 0.25% bupivacaine at 8 mL/h 20-mL 0.375% ropivacaine Postoperative infusion: 0.25% bupivacaine at 8 mL/h 20-mL 0.375% levobupivacaine Postoperative infusion: 0.2% ropivacaine at 8 mL/h 20-mL 0.375% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8 h for 48 h 30-mL 0.25% bupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8 h for 48 h 30-mL 0.25% bupivacaine Postoperative infusion: 0.2% ropivacaine at 20 mL/8 h for 48 h 30-mL 0.25% bupivacaine Prone Supine Aygun et al ⁵³ T3/T4 30-mL mixture of 15-mL 0.5% bupivacaine + 7.5-mL 2% lidocaine + 7.5-mL		Kwon et al 56	10	30-mL 0.375% ropivacaine with epinephrine
Prince wery 12 h for 48 hAltiparmak et al (2018)3420-mL 0.25% bupivacaineJain et al4120-mL 0.25% bupivacaineOhgoshi et al32Postoperative infusion: 0.25% bupivacaine at 5-mL/h for 72 hOhgoshi et al32Postoperative infusion: 0.25% bupivacaine at 8 mL/hTanaka et al47Postoperative infusion: 0.2% ropivacaine at 8 mL/hUeshima and Otake4920-mL 0.375% levobupivacaineOrozco et al57T6ProneGurkan et al (2018)40T4SupineAygun et al63T3/T4SupineAygun et al63T3/T4				Postoperative infusion: bolus of 30-mL 0.375% ropivacaine with
Altiparmak et al (2018)34 Jain et al4120-mL 0.25% bupivacaine 20-mL 0.25% bupivacaine Postoperative infusion: 0.25% bupivacaine at 5-mL/h for 72 h 20-mL 0.375% ropivacaine Postoperative infusion: 0.2% ropivacaine at 8mL/h 20-mL 0.375% levobupivacaine and Otake49 Orozco et al57Postoperative infusion: 0.2% ropivacaine at 8mL/h 20-mL 0.375% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20mL/8h for 48 h 30-mL 0.25% levobupivacaineProneGurkan et al (2018)40T4 T4 T3/T420-mL 0.25% bupivacaine Postoperative infusion: 0.1% levobupivacaine at 20mL/8h for 48 h 30-mL 0.25% levobupivacaine				epinephrine every 12 h for 48 h
Jain et al ⁴¹ 20-mL 0.25% bupivacaine Postoperative infusion: 0.25% bupivacaine at 5-mL/h for 72 h 20-mL 0.375% ropivacaine Postoperative infusion: 0.2% ropivacaine at 8mL/h 20-mL 0.375% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8 h for 48 h 30-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8 h for 48 h 30-mL 0.25% levobupivacaine Porone Gurkan et al (2018) ⁴⁰ T4 Supine Aygun et al ⁶³ T3/T4 30-mL mixture of 15-mL 0.5% bupivacaine + 7.5-mL 2% lidocaine + 7.5-mL		Altiparmak et al (2018) ³⁴		20-mL 0.25% bupivacaine
Postoperative infusion: 0.25% bupivacaine at 5-mL/h for 72 h 20-mL 0.375% ropivacaine Postoperative infusion: 0.2% ropivacaine at 8mL/h 20-mL 0.375% levobupivacaine at 8mL/h 20-mL 0.375% levobupivacaine at 20mL/8 h for 48 h 20-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20mL/8 h for 48 h 30-mL 0.25% levobupivacaine Prone Gurkan et al (2018) ⁴⁰ Supine Aygun et al ⁶³ T3/T4 Postoperative infusion: 0.2% ropivacaine at 20mL/8 h for 48 h 30-mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20mL/8 h for 48 h 30-mL 0.25% levobupivacaine Prone Gurkan et al (2018) ⁴⁰ T4 20-mL 0.25% bupivacaine Prome Aygun et al ⁶³ T3/T4 Postoperative infusion: 0.2% ropivacaine at 20mL/8 h for 48 h 30-mL 0.25% levobupivacaine Prome function Prome Aygun et al ⁶³ T3/T4 Prome Prome Pr		Jain et al ⁴¹		20-mL 0.25% bupivacaine
Ohgoshi et al3220-mL 0.375% ropivacaineTanaka et al47Postoperative infusion: 0.2% ropivacaine at 8 mL/hTanaka et al47Postoperative infusion: 0.2% ropivacaine at 20 mL/8 h for 48 hUeshima and Otake49Postoperative infusion: 0.1% levobupivacaine at 20 mL/8 h for 48 hOrozco et al57T6ProneGurkan et al (2018)40SupineAygun et al63T3/T430-mL mixture of 15-mL 0.5% bupivacaine + 7.5-mL 2% lidocaine + 7.5-mL		0		Postoperative infusion: 0.25% bupivacaine at 5-mL/h for 72 h
Postoperative infusion: 0.2% ropivacaine at 8 mL/h 20 mL 0.375% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8 h for 48 h 30 mL 0.25% levobupivacaine Postoperative infusion: 0.1% levobupivacaine at 20 mL/8 h for 48 h 30 mL 0.25% bupivacaine Prone Gurkan et al (2018) ⁴⁰ T4 20 mL mixture of 0.25% bupivacaine Supine Aygun et al ⁶³ T3/T4 30 mL mixture of 15 mL 0.5% bupivacaine + 7.5 mL 2% lidocaine + 7.5 mL		Ohgoshi et al ³²		20-mĹ 0.375% ropivacaine
Tanaka et al20-mL 0.375% levobupivacainePostoperative infusion: 0.1% levobupivacaine at 20 mL/8h for 48 hUeshima and OtakePostoperative infusion: 0.1% levobupivacaine at 20 mL/8h for 48 hOrozco et al30-mL 0.25% levobupivacaineProneGurkan et al (2018)SupineAygun et alOrozco et alT3/T4SupineAygun et alOrozco et alT3/T4Orozco et alT3/T4				Postoperative infusion: 0.2% ropivacaine at 8mL/h
Postoperative infusion: 0.1% levobupivacaine at 20 mL/8 h for 48 h 30-mL 0.25% levobupivacaine Orozco et al ⁵⁷ T6 20-mL mixture of 0.25% bupivacaine with epinephrine + 0.5% lidocaine Prone Gurkan et al (2018) ⁴⁰ T4 20-mL 0.25% bupivacaine Supine Aygun et al ⁶³ T3/T4 30-mL mixture of 15-mL 0.5% bupivacaine + 7.5-mL 2% lidocaine + 7.5-mL		Tanaka et al ⁴⁷		20-mL 0.375% levobupivacaine
Ueshima and Otake*30-mL 0.25% levobupivacaineOrozco et alT6ProneGurkan et al (2018)**SupineAygun et alGurkan et alT3/T4SupineT3/T4 <td></td> <td>U 1: 10/149</td> <td></td> <td>Postoperative infusion: 0.1% levobupivacaine at $20 \text{ mL}/8 \text{ h}$ for 48 h</td>		U 1: 10/149		Postoperative infusion: 0.1% levobupivacaine at $20 \text{ mL}/8 \text{ h}$ for 48 h
Prone Gurkan et al (2018) ⁴⁰ T4 20-mL mixture of 0.25% bupivacaine with epinephrine + 0.5% lidocaine Supine Aygun et al ⁶³ T3/T4 30-mL mixture of 15-mL 0.5% bupivacaine + 7.5-mL 2% lidocaine + 7.5-mL		Ueshima and Otake ⁴³	TC	30-mL 0.25% levobupivacaine
Supine Aygun et al ⁶³ T3/T4 30-mL mixture of 15-mL 0.5% bupivacaine + 7.5-mL 2% lidocaine + 7.5-mL	Dropo	Curken et al (9018) ⁴⁰	10 T4	20-IIL IIIXture of 0.25% bupivacaine with epinephrine + 0.5% lidocaine
Suprice Arguneta 15/14 Some intention of 15-intension outproceanter 7.5-inte 270 indocanter 7.5-inte	Supine	Avoun et a^{163}	T3/T4	30 mL mixture of 15 mL 0.5% hunivacaine + 75 mL 9% lidocaine + 75 mL
normal saune	Supine	nygun et al	15/11	normal saline

Table 2. ESPB Technique as Performed in Included Articles

and is relatively safe due to the lack of vital structures in the immediate vicinity that are at risk of needle injury.⁴¹ Except for 1 case report where the patient developed a pneumothorax secondary to ESPB,⁶² there have been no major complications associated with the block according to this systematic review, and other reviews on regional anesthesia.⁶⁶ As part of a multimodal pain analgesia, ESPB in breast surgery can help provide more effective perioperative pain management, and as such reduce postoperative pain and opioid requirement, leading to enhanced recovery and a shorter length of hospital stay. Finally, this technique may allow breast surgeries to be performed in an ambulatory setting, without the use of general anesthesia.⁶⁷

Although the results of this review are promising, it has several limitations. The main one is the lack of quantitative analysis, which is due to the limited number of RCTs and the heterogeneity of the breast procedures performed, and the outcomes measured. This review included different study types such as case series and RCTs which hinder the level of evidence and conclusions of this review. The majority of RCTs excluded patients with ASA score of more than 2, and given the importance of avoiding general anesthesia and reducing opioid consumption in higher risk patients (ASA>2), the authors of this study decided to include case reports/series to more accurately report the benefits of ESPB in these patient populations.

Future studies should aim to investigate the variables that impact the spread of ESPB, such as patient position, age, and body habitus. In addition, future studies should aim to confirm whether ESPB provides adequate analgesia to the whole breast region via pinprick sensation testing. Furthermore, more RCTs should be conducted to verify the efficacy of ESPB compared with other widely used regional blocks, such as PVB and serratus anterior block. Future studies should also conduct cost-benefit analyses of ESPB which would provide great incentive in setting guidelines for breast perioperative pain control. Finally, none of the reviewed studies measure long-term opioid use.

CONCLUSIONS

Given the prevalence of breast surgery, its risk for chronic postoperative pain, and the prolonged postoperative opioid use, there is growing interest for improved perioperative pain control using regional anesthesia.^{16,23} The ESPB is a promising form of regional anesthesia that can decrease postoperative pain and opioid consumption when used as part of multimodal pain analgesia. The technique is easy to perform under ultrasound guidance with a very low rate of complications.

Jeffrey E. Janis, MD, FACS

Department of Plastic Surgery Ohio State University Wexner Medical Center 915 Olentangy River Road, Suite 2100 Columbus, OH 43212 E-mail: Jeffrey.Janis@osumc.edu

REFERENCES

 Wallace MS, Wallace AM, Lee J, et al. Pain after breast surgery: a survey of 282 women. *Pain*. 1996;66:195–205.

- Langford DJ, Paul SM, West C, et al. Persistent breast pain following breast cancer surgery is associated with persistent sensory changes, pain interference, and functional impairments. *J Pain*. 2014;15:1227–1237.
- 3. Wang L, Guyatt GH, Kennedy SA, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. *Cmaj.* 2016;188: E352–E361.
- 4. Thorarinsson A, Fröjd V, Kölby L, et al. Long-term health-related quality of life after breast reconstruction: comparing 4 different methods of reconstruction. *Plast Reconstr Surg Glob Open*. 2017;5:e1316.
- Bailey CR, Ogbuagu O, Baltodano PA, et al. Quality-of-life outcomes improve with nipple-sparing mastectomy and breast reconstruction. *Plast Reconstr Surg*. 2017;140:219–226.
- 6. Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. *J Pain Res.* 2017;10:2287–2298.
- 7. Hidding JT, Beurskens CH, van der Wees PJ, et al. Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review. *PloS One.* 2014;9:e96748.
- Ter Louw RP, Nahabedian MY. Prepectoral breast reconstruction. *Plast Reconstr Surg.* 2017;140(5S Advances in Breast Reconstruction):518–598.
- Sbitany H, Piper M, Lentz R. Prepectoral breast reconstruction: a safe alternative to submuscular prosthetic reconstruction following nipple-sparing mastectomy. *Plast Reconstr Surg.* 2017;140:432–443.
- Turan M, Karaman Y, Karaman S, et al. Postoperative chronic pain after breast surgery with or without cancer: follow up 6 months: 14AP1-7. *Eur J Anaesthesiol (EJA)*. 2014;31:216.
- Kulkarni AR, Pusic AL, Hamill JB, et al. Factors associated with acute postoperative pain following breast reconstruction. *JPRAS Open*. 2017;11:1–13.
- 12. Jones MR, Viswanath O, Peck J, et al. A brief history of the opioid epidemic and strategies for pain medicine. *Pain Ther.* 2018;7:13–21.
- Dowell D, Zhang K, Noonan RK, et al. Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. *Health Aff (Millwood)*. 2016;35:1876–1883.
- Joshi GP. Putting it all together: recommendations for improving pain management in plastic surgical procedures. *Plast Reconstr* Surg. 2014;134(4 Suppl 2):94S–100S.
- Barker JC, DiBartola K, Wee C, et al. Preoperative multimodal analgesia decreases postanesthesia care unit narcotic use and pain scores in outpatient breast surgery. *Plast Reconstr Surg.* 2018;142:443e–450e.
- 16. Olds C, Spataro E, Li K, et al. Assessment of persistent and prolonged postoperative opioid use among patients undergoing plastic and reconstructive surgery. *JAMA Facial Plast Surg.* 2019;21:286–291.
- Demsey D, Carr NJ, Clarke H, et al. Managing opioid addiction risk in plastic surgery during the perioperative period. *Plast Reconstr Surg.* 2017;140:613e–619e.
- Park KU, Kyrish K, Terrell J, et al; other members of Department of Breast Surgical Oncology Study Group. Surgeon perception versus reality: opioid use after breast cancer surgery. J Surg Oncol. 2019;119:909–915.
- Curatolo M. Regional anesthesia in pain management. Curr Opin Anaesthesiol. 2016;29:614–619.
- Kettner SC, Willschke H, Marhofer P. Does regional anaesthesia really improve outcome? Br J Anaesth. 2011;107(Suppl 1):i90–i95.
- Garg R, Bhan S, Vig S. Newer regional analgesia interventions (fascial plane blocks) for breast surgeries: review of literature. *Indian J Anaesth.* 2018;62:254–262.

- Sekandarzad MW, van Zundert AAJ, Lirk PB, et al. Perioperative anesthesia care and tumor progression. *Anesth Analg.* 2017;124:1697–1708.
- Woodworth GE, Ivie RMJ, Nelson SM, et al. Perioperative breast analgesia: a qualitative review of anatomy and regional techniques. *Reg Anesth Pain Med.* 2017;42:609–631.
- Thomas M, Philip FA, Mathew AP, et al. Intraoperative pectoral nerve block (pec) for breast cancer surgery: a randomized controlled trial. *J Anaesthesiol Clin Pharmacol.* 2018;34:318–323.
- Naja Z, Lönnqvist PA. Somatic paravertebral nerve blockade. Incidence of failed block and complications. *Anaesthesia*. 2001;56:1184–1188.
- Pace MM, Sharma B, Anderson-Dam J, et al. Ultrasound-guided thoracic paravertebral blockade: a retrospective study of the incidence of complications. *Anesth Analg.* 2016;122:1186–1191.
- Ueshima H, Otake H. Ultrasound-guided pectoral nerves (PECS) block: complications observed in 498 consecutive cases. *J Clin Anesth.* 2017;42:46.
- Bakshi SG, Karan N, Parmar V. Pectoralis block for breast surgery: a surgical concern? *Indian J Anaesth.* 2017;61:851–852.
- Forero M, Adhikary SD, Lopez H, et al. The erector spinae plane block: a novel analgesic technique in thoracic neuropathic pain. *Reg Anesth Pain Med.* 2016;41:621–627.
- **30.** Adhikary SD, Pruett A, Forero M, et al. Erector spinae plane block as an alternative to epidural analgesia for post-operative analgesia following video-assisted thoracoscopic surgery: a case study and a literature review on the spread of local anaesthetic in the erector spinae plane. *Indian J Anaesth.* 2018;62:75–78.
- **31.** Fang B, Wang Z, Huang X. Ultrasound-guided preoperative single-dose erector spinae plane block provides comparable analgesia to thoracic paravertebral block following thoracotomy: a single center randomized controlled double-blind study. *Ann Transl Med.* 2019;7:174.
- 32. Ohgoshi Y, Ikeda T, Kurahashi K. Continuous erector spinae plane block provides effective perioperative analgesia for breast reconstruction using tissue expanders: a report of two cases. J Clin Anesth. 2018;44:1–2.
- Singh S, Chowdhary NK. Erector spinae plane block an effective block for post-operative analgesia in modified radical mastectomy. *Indian J Anaesth.* 2018;62:148–150.
- 34. Altiparmak B, Korkmaz Toker M, Uysal Aİ, et al. Comparison of the effects of modified pectoral nerve block and erector spinae plane block on postoperative opioid consumption and pain scores of patients after radical mastectomy surgery: a prospective, randomized, controlled trial. J Clin Anesth. 2019;54:61–65.
- Bonvicini D, Giacomazzi A, Pizzirani E. Use of the ultrasoundguided erector spinae plane block in breast surgery. *Minerva Anestesiol*. 2017;83:1111–1112.
- **36.** Bonvicini D, Tagliapietra L, Giacomazzi A, et al. Bilateral ultrasound-guided erector spinae plane blocks in breast cancer and reconstruction surgery. *J Clin Anesth.* 2018;44:3–4.
- 37. De Cassai A, Bonvicini D, Ruol M, et al. Erector spinae plane block combined with a novel technique for selective brachial plexus block in breast cancer surgery -a case report. *Korean J Anesthesiol.* 2019;72:270–274.
- 38. De Cassai A, Marchet A, Ori C. The combination of erector spinae plane block and pectoralis blocks could avoid general anesthesia for radical mastectomy in high risk patients. *Minerva Anestesiol.* 2018;84:1420–1421.
- **39.** Finneran JJ, Gabriel RA, Khatibi B. Erector spinae plane blocks provide analgesia for breast and axillary surgery: a series of 3 cases. *Reg Anesth Pain Med.* 2018;43:101–102.
- 40. Gürkan Y, Aksu C, Kuş A, et al. Ultrasound guided erector spinae plane block reduces postoperative opioid consumption following breast surgery: a randomized controlled study. *J Clin Anesth.* 2018;50:65–68.

- **41.** Jain K, Jaiswal V, Puri A. Erector spinae plane block: relatively new block on horizon with a wide spectrum of application a case series. *Indian J Anaesth.* 2018;62:809–813.
- **42.** Kimachi PP, Martins EG, Peng P, et al. The erector spinae plane block provides complete surgical anesthesia in breast surgery: a case report. *A A Pract.* 2018;11:186–188.
- 43. Kumar A, Hulsey A, Martinez-Wilson H, et al. The use of liposomal bupivacaine in erector spinae plane block to minimize opioid consumption for breast surgery: a case report. *A A Pract.* 2018;10:239–241.
- 44. Nair AS, Seelam S, Naik V, et al. Opioid-free mastectomy in combination with ultrasound-guided erector spinae block: a series of five cases. *Indian J Anaesth.* 2018;62:632–634.
- 45. Oksuz G, Bilgen F, Arslan M, et al. Ultrasound-guided bilateral erector spinae block versus tumescent anesthesia for postoperative analgesia in patients undergoing reduction mammoplasty: a randomized controlled study. *Aesthetic Plast Surg.* 2019;43:291–296.
- **46**. Talawar P, Kumar A, Bhoi D, et al. Initial experience of erector spinae plane block in patients undergoing breast surgery: a case series. *Saudi J Anaesth.* 2019;13:72–74.
- 47. Tanaka N, Ueshima H, Otake H. Erector spinae plane block for combined lovectomy and radical mastectomys. *J Clin Anesth.* 2018;45:27–28.
- Ueshima H, Otake H. Limitations of the erector spinae plane (ESP) block for radical mastectomy. *J Clin Anesth.* 2018; 51:97.
- **49**. Ueshima H, Otake H. Erector spinae nerve block for breast surgery using the lateral approach. *J Clin Anesth.* 2019;56:57.
- Veiga M, Costa D, Brazão I. Erector spinae plane block for radical mastectomy: a new indication? *Rev Esp Anestesiol Reanim.* 2018;65:112–115.
- **51.** Altuparmak B, Korkmaz Toker M, Uysal Aİ, et al. Comparison of the efficacy of erector spinae plane block performed with different concentrations of bupivacaine on postoperative analgesia after mastectomy surgery: randomized, prospective, double blinded trial. *BMC Anesthesiol.* 2019;19:31.
- 52. Altiparmak B, Korkmaz Toker M, Uysal Aİ, et al. Ultrasound guided erector spinae plane block for postoperative analgesia after augmentation mammoplasty: case series. *Rev Bras Anesthesiol.* 2019;69:307–310.
- **53.** Gad M, Abdelwahab K, Abdallah A, et al. Ultrasound-guided erector spinae plane block compared to modified pectoral plane block for modified radical mastectomy operations. *Anesth Essays Res.* 2019;13:334–339.
- 54. Singh S, Kumar G, Akhileshwar. Ultrasound-guided erector spinae plane block for postoperative analgesia in modified radical mastectomy: a randomised control study. *Indian J Anaesth.* 2019;63:200–204.
- 55. Balaban O, Aydin T, Yaman M. Is ultrasound guided erector spinae plane block sufficient for surgical anesthesia in minor surgery at thoracal region? *J Clin Anesth.* 2018;47:7–8.
- 56. Kwon WJ, Bang SU, Sun WY. Erector spinae plane block for effective analgesia after total mastectomy with sentinel or axillary lymph node dissection: a report of three cases. *J Korean Med Sci.* 2018;33:e291.
- 57. Orozco E, Serrano RE, Rueda-Rojas VP. Erector spinae plane (ESP) block for postoperative analgesia in total radical mastectomy: case report. *Colombian Journal of Anesthesiology*. 2018;46(2S):66–68.
- Piraccini E, Biondi G, Corso RM, et al. The use of rhomboid intercostal block, parasternal block and erector spinae plane block for breast surgery. *J Clin Anesth.* 2019;59:10.
- Ueshima H. Bilateral erector spinae nerve block using one injection for bilateral breast cancer surgery. J Clin Anesth. 2019;56:131.

- 60. Selvi O, Tulgar S. Use of the ultrasound-guided erector spinae plane block in segmental mastectomy. *Turk J Anaesthesiol Reanim.* 2019;47:158–160.
- **61.** Kim D, Bang S, Sun WY. Erector spinae plane block with sedation for surgical anesthesia in breast conserving surgery. *J Clin Anesth.* 2019;57:50.
- 62. Ueshima H. Pneumothorax after the erector spinae plane block. *J Clin Anesth.* 2018;48:12.
- 63. Aygun H, Thomas DT, Tulgar S. The "dry leaf" technique for erector spinae plane block in supine position: an alternative to lateral decubitus or prone position. J Clin Anesth. 2019;59:34–35.
- 64. Brookes J, Dhir S. Regional anesthesia for the high-risk patient. In: McConachie I, ed. Anesthesia and Perioperative Care of the High-Risk Patient. 3 ed. Cambridge, United Kingdom: Cambridge University Press; 2014:214–230.
- 65. El-Boghdadly K, Pawa A. The erector spinae plane block: plane and simple. *Anaesthesia*. 2017;72:434–438.
- 66. Ardon AE, Prasad A, McClain RL, et al. Regional anesthesia for ambulatory anesthesiologists. *Anesthesiol Clin.* 2019;37:265–287.
- Tan E, Han Pek C, Tey Boon Lim J. Ambulatory surgery for the patient with breast cancer: current perspectives. *Open Access* Surgery. 2016;9:65-70.